Article
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster…
Read More
A tool for reconstruction of a 3D model of the knee from 2D X-ray images is being evaluated on clinical data at a leading medical center with promising results Excerpt from the Press Release: TEL AVIV, Israel and SAN JOSE, Calif., Oct. 27, 2022 /PRNewswire/ — RSIP Vision, an experienced developer of groundbreaking AI technologies for…
Read More
L-Dex Found to be a Cost Effective, Reproducible, and Practical Method to Monitor Breast Cancer Patients for Early Signs of Lymphedema Excerpt from the Press Release: CARLSBAD, Calif., Oct. 26, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD) is pleased to announce publication of a systematic literature review showing that early detection and intervention of breast…
Read More
MT-101 is the First mRNA-Engineered CAR Monocyte Therapy to be Dosed in Humans Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed…
Read More
Excerpt from the Press Release: WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research. The publication includes clinical data from the company’s randomized,…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.…
Read More
Positive Phase 1 Data Support Near-term Initiation of Global Phase 2 Trial Excerpt from the Press Release: CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that data from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022. Mr. Kapur is the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. “Anil’s deep…
Read More
Excerpt from the Press Release: BOSTON, Oct. 20, 2022 /PRNewswire/ — IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozen Euploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116). The PROGRESS study is a multicenter, randomized, controlled, double-blind, double-dummy study to evaluate the safety…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successfully completed the dosing of first patient in the global phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in the United States. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,…
Read More